Spero Therapeutics, Inc.
Returns on Capital
| Period | ROE | ROI | ROA |
|---|---|---|---|
| Dec 2016 | 15.9% | 15.9% | -52.4% |
| Sep 2017 | 12.0% | 12.0% | -31.2% |
| Dec 2017 | -16.4% | -16.4% | -14.8% |
| Mar 2018 | -14.3% | -14.3% | -13.1% |
| Jun 2018 | -15.2% | -15.2% | -13.7% |
| Sep 2018 | -8.4% | -8.4% | -7.7% |
| Dec 2018 | -9.2% | -9.2% | -8.2% |
| Mar 2019 | -4.5% | -4.5% | -4.1% |
| Jun 2019 | -12.1% | -12.1% | -10.8% |
| Sep 2019 | -19.1% | -19.1% | -15.7% |
| Dec 2019 | -33.5% | -33.5% | -23.5% |
| Mar 2020 | -28.3% | -28.3% | -21.2% |
| Jun 2020 | -23.7% | -23.7% | -17.9% |
| Sep 2020 | -14.2% | -14.2% | -12.0% |
| Dec 2020 | -14.1% | -14.1% | -12.1% |
| Mar 2021 | -16.3% | -16.3% | -13.5% |
| Jun 2021 | -20.6% | -20.6% | -15.6% |
| Sep 2021 | -20.1% | -20.1% | -15.6% |
| Dec 2021 | -33.2% | -33.2% | -17.1% |
| Mar 2022 | -52.5% | -52.5% | -22.5% |
| Jun 2022 | -79.9% | -79.9% | -45.1% |
| Sep 2022 | -36.0% | -36.0% | -18.1% |
| Dec 2022 | 35.3% | 35.3% | 21.5% |
| Mar 2023 | -20.5% | -20.5% | -11.8% |
| Jun 2023 | -21.7% | -21.7% | -12.0% |
| Sep 2023 | -6.0% | -6.0% | -3.0% |
| Dec 2023 | 47.9% | 47.9% | 28.1% |
| Mar 2024 | -13.2% | -13.2% | -7.6% |
| Jun 2024 | -22.2% | -22.2% | -11.9% |
| Sep 2024 | -26.2% | -26.2% | -12.7% |
| Dec 2024 | -45.3% | -45.3% | -18.9% |
| Mar 2025 | -41.0% | -41.0% | -17.8% |
| Jun 2025 | -5.2% | -5.2% | -2.7% |
| Sep 2025 | -27.9% | -27.9% | -13.6% |
| Dec 2025 | 53.4% | 53.4% | 45.7% |
| Mar 2026 | -13.6% | -13.6% | -12.2% |
| Jun 2026 | -21.6% | -21.6% | -18.1% |